TH-302 Combination Therapy for PARP-Resistant Tumor Hypoxia

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

PARP inhibitor resistance in cancer treatment, particularly in BRCA-mutated tumors, limits the effectiveness of current therapies, necessitating the development of alternative treatment strategies.

Innovation Solution

Utilizing a hypoxia-activated compound, such as TH-302, either as a monotherapy or in combination with a PARP inhibitor, to target and treat PARP inhibitor-resistant cancers by exploiting the compound's selective cytotoxicity in hypoxic tumor environments.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If PARP inhibitors are used to treat BRCA-mutated tumors, then tumor cell growth is inhibited through synthetic lethality, but PARP inhibitor resistance develops limiting long-term effectiveness

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidduration of treatment response

Core Design Contradiction:

ReliabilityVSDuration of action of stationary object

Solution Approach 1:

The patent combines a hypoxia-activated prodrug (TH-302) with a PARP inhibitor to create a combination therapy regimen. The prodrug component activates selectively in hypoxic tumor regions to generate cytotoxic radicals that damage DNA, while the PARP inhibitor blocks DNA repair pathways. This merging of two different mechanisms of action addresses resistance by attacking tumor cells through multiple pathways simultaneously, preventing the development of single-point resistance mutations.

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The patent utilizes the parameter change of oxygen concentration to control drug activation. The hypoxia-activated prodrug remains inactive in normoxic conditions but becomes cytotoxic in hypoxic tumor microenvironments. This parameter-based activation strategy allows selective targeting of resistant tumor regions that often exhibit hypoxia, thereby extending effective treatment duration by specifically addressing the resistant subpopulation.

Inventive Principle:

Principle #35Parameter changes

2Productivity

If combination therapy with hypoxia-activated prodrug and PARP inhibitor is used, then additive effect in inhibiting tumor growth is achieved, but treatment complexity increases

Engineering Contradiction:

Improvetumor growth inhibition efficacyVSAvoidtreatment regimen complexity

Core Design Contradiction:

ProductivityVSDevice complexity

Solution Approach 1:

The hypoxia-activated prodrug serves as a self-service system that automatically activates in response to the hypoxic conditions inherent in tumor microenvironments. The drug's activation is driven by the tumor's own metabolic characteristics rather than requiring external activation mechanisms. This self-activating property simplifies the combination therapy by eliminating the need for complex delivery systems or external triggers, reducing overall treatment complexity while maintaining high efficacy.

Inventive Principle:

Principle #25Self-service

3Reliability

If hypoxia-activated prodrug is used as monotherapy or combination therapy, then therapeutic efficacy is achieved in PARP-resistant models, but selective activation in hypoxic environments requires specific chemical mechanisms

Engineering Contradiction:

Improvetherapeutic efficacy in resistant modelsVSAvoiddrug activation mechanism complexity

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent replaces complex mechanical or enzymatic activation systems with a chemical reduction mechanism. The prodrug contains a nitroimidazole group that undergoes one-electron reduction by cellular reductases under hypoxic conditions to generate cytotoxic radical intermediates. This chemical substitution approach simplifies the activation mechanism compared to enzyme-dependent or externally-triggered systems, making the drug more manufacturable and clinically feasible while maintaining reliable activation in hypoxic tumor environments.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The combination therapy demonstrates an additive effect in inhibiting tumor growth and shows therapeutic efficacy even in PARP-resistant models, offering a potential solution to overcome resistance and enhance treatment outcomes.

Implementation Method 1

the mechanism of one-electron reductase-dependent activity enhancement by TH-302 under hypoxia has been confirmed

Methodology Applied

Scientific EffectOne-electron reduction: Redox Reactions

Implementation Method 2

the activity of inducing H2AX phosphorylation and DNA crossing-linking, leading to cell cycle arrest

Methodology Applied

Scientific EffectDNA cross-linking: Chemical Bonding

Data Source

PatentUS20250387419A1PARP inhibitor-resistant patient treated with th-302

Publication Date: 2025.12.25 SHENZHEN ASCENTAWITS PHARM TECH CO LTD

AI summary

The present invention provides a treatment method for treating a PARP inhibitor-resistant patient with TH-302 alone or in combination, a drug, and a pharmaceutical use thereof. The drug may contain a hypoxia activated compound of formula (I) as follows:where each R is independently selected from H, —CH3 and —CH2CH3, and each X is independently selected from Cl, Br, MsO, TsO and other leaving functional groups.